C9orf72 and amyotrophic lateral sclerosis: The present study reveals that Type I PRMT inhibitors can completely abrogate toxicity produced by exogenous polyGR and polyPR challenge in NSC34 cells and suggests that Type I PRMT inhibition is a potential therapeutic strategy for C9orf72-associated ALS.